PARTNER: A randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first‑line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Authors

Lori J. Wirth

Massachusetts General Hospital, Boston, MA

Lori J. Wirth , Shaker R. Dakhil , Gabriela Kornek , Rita Axelrod , Douglas Adkins , Shubham Pant , Paul E. O'Brien , Philip R. Debruyne , Kelly S. Oliner , Jun Dong , Bruce A. Bach

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs).

First Author: William Nassib William Jr.

insert_chart_outlined

Poster

2015 Gastrointestinal Cancers Symposium

bookmark_border

First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5- fluorouracil (DCF) plus panitumumab (P) in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction (GEJ): A phase II multicenter trial.

First Author: Gianluca Tomasello

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.

First Author: J. Guigay

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).

First Author: Liqiong Xue